Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M. Gatell, Nadine Ktorza, Graeme Moyle et al.|Clinical Infectious Diseases|2018Cited by 48